Comparison of Alemtuzumab and Anti-thymocyte Globulin Treatment for Acute Kidney Allograft Rejection

Comparison of Alemtuzumab and Anti-thymocyte Globulin Treatment for Acute Kidney Allograft Rejection

Rabbit anti-thymocyte globulin (rATG) is currently the treatment of choice for glucocorticoid-resistant, recurrent, or severe acute allograft rejection (AR). However, rATG is associated with severe infusion-related side effects. Alemtuzumab is incidentally given to kidney transplant recipients as tr...

Full description

Bibliographic Details
Main Authors: Marieke van der Zwan, Marian C. Clahsen-Van Groningen, Martijn W. F. van den Hoogen, Marcia M. L. Kho, Joke I. Roodnat, Katya A. L. Mauff, Dave L. Roelen, Madelon van Agteren, Carla C. Baan, Dennis A. Hesselink
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-07-01
Series:Frontiers in Immunology
Subjects:
alemtuzumab
allograft rejection
rabbit anti-thymocyte globulin
kidney transplantation
T cell depletion
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.01332/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2020.01332/full

Similar Items